BioRestorative Therapies Inc
0.0496 (1.65%)
Upgrade to Real-Time
Regular Market
Volume 29,593
Bid Price 3.05
Ask Price 3.12
News (1)
Day High 3.28


52 Week Range


Day Low 3.02
Company Name Stock Ticker Symbol Market Type
BioRestorative Therapies Inc BRTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.0496 1.65% 3.06 14:28:24
Open Price Low Price High Price Close Price Prev Close
3.04 3.02 3.28 3.0104
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
222 29,593 $ 3.09 $ 91,524 - 2.46 - 5.975
Last Trade Time Type Quantity Stock Price Currency
14:28:23 100 $ 3.06 USD


Draw Mode:

BioRestorative Therapies Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 11.24M 3.67M 2.85M $ 46.00k $ - -38.33 -0.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 4.94k 21.80%

more financials information »

BioRestorative Therapies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical BRTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.023.322.853.109,8300.041.32%
1 Month3.003.322.853.066,1820.062.0%
3 Months3.004.402.553.2015,1550.062.0%
6 Months3.464.402.463.1513,300-0.40-11.56%
1 Year3.795.9752.464.1924,079-0.73-19.26%
3 Years8.908.902.465.00109,757-5.84-65.62%
5 Years8.908.902.465.00109,757-5.84-65.62%

BioRestorative Therapies Description

BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.